- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04864938
Recovery After Critical Covid-19 Infection (RECOVID)
Studienübersicht
Status
Bedingungen
Detaillierte Beschreibung
Eligible patients who have been treated in the intensive care units of Helsinki University Hospital are invited to participate. Controls are recruited from follow-up clinics, and with announcements in media and websites.
The participants receive an invitation to a follow-up clinic where their experiences from the ICU treatment and recovery will be discussed. The investigators will perform neuropsychologic testing (6 months post-discharge), a telephone interview (3 months) and send written questionnaires (3, 6 and 24 months) to the participants. The participants will undergo MRI imaging of the brain and laboratory tests will be taken. The olfactory function will be tested at a follow-up clinic. Data on the patients´ respiratory function from clinical spirometry and diffusion capacity testing 3 and 6 months after discharge are collected. The patients will perform a 6 min walk test.
Data on coagulation laboratory values will be registered from acute phase and 6 months after discharge. The investigators will also analyse ApoE alleles, neurofilament light and NAD-metabolites and study their correlation with neuropsychologic findings and long term symptoms (up to 5 years after hospital discharge).
Participants will also undergo magnetic resonance imaging of the heart at 6-12 months after the hospital discharge, and laboratory samples, a symptom questionnaire and electrocardiogram are collected. Inflammatory parameters and variables associated with regulating inflammation and coagulation will be analysed.
Clinical data from the acute and post-acute phase and demographic data are collected from the patient data management systems.
The target patient number is 75 intensive care treated patients and 50 control persons in each three control group.
Studientyp
Einschreibung (Voraussichtlich)
Kontakte und Standorte
Studienorte
-
-
Capital Province Of Finland
-
Helsinki, Capital Province Of Finland, Finnland, 00290
- Helsinki university hospital
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Age 18-100
- Positive PCR for Sars-CoV-2 (except non-covid controls, who must be negative)
- Native language Finnish or Swedish
- Informed consent to study to study participation
Exclusion Criteria:
- Age under 18
- Pregnant or lactating
- Major neurologic diagnosis (TBI, dementia, stroke, Parkinson´s disease before covid-19)
- Substantially impaired hearing or vision
- Developmental disability.
- No consent to study participation
- Contraindication to MR imaging (such as cardiac pacemaker, allergy to contrast)
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Kohorten und Interventionen
Gruppe / Kohorte |
|---|
|
Patients: ICU treated covid-19 patients
Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
|
|
Control group 1, covid-19 patients treated in the regular wards
As above, without 6 minute walk test or routine chest x-ray
|
|
Control group 2, persons with covid-19 without hospitalization
As above, but without respiratory testing
|
|
Control group 3, non-covid controls
As control group 2
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Cognitive function 6 months after hospital discharge
Zeitfenster: 6 months after hospital discharge
|
Global score calculated from three domains: memory, executive functions and attention.Memory: WMS-III Word list delayed recall + WMS-III Logical memory delayed recall + Rey Complex Figure, delayed recall Executive: TMB (time, reversed) + Stroop interference (time, reversed) + FAB score Attention: WAIS-IV Coding + CPT (correct items) + Stroop naming (time, reversed) The global score will be compared with controls and age matched national references
|
6 months after hospital discharge
|
|
Diffusion capacity 6 months after hospital discharge
Zeitfenster: 6 months after hospital discharge
|
Diffusion capacity DLCO results (percentage of predicted) 6 months after ICU treatment for covid-19
|
6 months after hospital discharge
|
|
Incidence of post myocarditis findings in MRI of the heart
Zeitfenster: 6-12 months after hospital discharge
|
Incidence of findings in cardiac MRI indicating previous myocarditis in each group
|
6-12 months after hospital discharge
|
|
Six minute walk test distance
Zeitfenster: 6 months after hospital discharge
|
The distance in meters walked by ICU treated patients in 6 minutes in controlled test environment
|
6 months after hospital discharge
|
|
Restriction in lung function tests
Zeitfenster: 6 months after hospital discharge
|
Restriction in lung function parameters vital capacity and forced vital capacity (z-scores) in measured by spirometry
|
6 months after hospital discharge
|
|
Cerebral microbleeds
Zeitfenster: 6 months after hospital discharge
|
Number and anatomical distribution of cerebral microbleeds in MRI imaging of the brain
|
6 months after hospital discharge
|
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 6 months after hospital discharge
Zeitfenster: 6 moths after hospital discharge
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 levels in ng/mL 6 months after hospital discharge
|
6 moths after hospital discharge
|
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
Zeitfenster: 6 months after hospital discharge
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
|
6 months after hospital discharge
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Correlation ApoE 4 alleles with disease severity
Zeitfenster: 6 months post-covid
|
Laboratory analysis of ApoE alleles and comparison of their frequencies among groups
|
6 months post-covid
|
|
Correlation of cerebral microbleeds with neuropsychological global score
Zeitfenster: 6 moths after hospital discharge
|
Correlation of type and location of cerebral microbleeds with neuropsychological global score
|
6 moths after hospital discharge
|
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
Zeitfenster: 6-12 months after hospital discharge
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
|
6-12 months after hospital discharge
|
|
Correlation of plasma neurofilament with cerebral microbleeds
Zeitfenster: 6 months after hospital discharge
|
Correlation of plasma neurofilament with cerebral microbleeds in brain MR imaging
|
6 months after hospital discharge
|
|
Correlation of 6 minute walk test heart rate variables with cardiac function
Zeitfenster: 6-12 months after hospital discharge
|
Correlation of heart rate in rest, exercise and 5 minutes after exercise with cardiac output measured in heart MRI
|
6-12 months after hospital discharge
|
|
Correlation of matrix metalloproteinase 9 with diffusion capacity
Zeitfenster: 6 months after hospital discharge
|
Correlation of matrix metalloproteinase 9 (ng/mL) with lung diffusion capacity z-score
|
6 months after hospital discharge
|
Mitarbeiter und Ermittler
Sponsor
Publikationen und hilfreiche Links
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- HUS/1949/2020
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Covid-19
-
PfizerAktiv, nicht rekrutierendCOVID-19 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Covid-19 Impfungen | SARS-CoV-2-Infektion, COVID19 | COVID-19-Impfung | SARS-CoV-2-Infektion, COVID-19 | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionVereinigte Staaten
-
Shanghai Public Health Clinical CenterNoch keine Rekrutierung
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Abgeschlossen
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RekrutierungZustand nach COVID-19 | Nach COVID-19 | Post-COVID-19-Syndrom | Langes COVID-19-Syndrom | Zustand nach COVID-19 (PCC)Deutschland
-
PfizerRekrutierungErkrankungen der Atemwege | COVID-19 | Lungenentzündung | Lungenkrankheit | Coronavirus Krankheit 2019 | Coronavirus-Krankheit 2019 (COVID-19) | Covid-19 Infektion | Infektionen der oberen Atemwege | Infektion der Atemwege | COVID-19 (Coronavirus-Krankheit 2019) | COVID-19 SARS-CoV-2-InfektionBelgien
-
ModeX Therapeutics, An OPKO Health CompanyRekrutierungCOVID 19 | COVID-19 (Prävention)Vereinigte Staaten
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRekrutierungErmüdung | Post-COVID-19-Syndrom | Zustand nach COVID-19 | Post-COVID-Syndrom | Lange COVID-19 | Lang-COVID | Post-COVID-ZustandKanada
-
University of Missouri, Kansas CityNational Institute on Minority Health and Health Disparities (NIMHD)Aktiv, nicht rekrutierendCovid-19-TestverhaltenVereinigte Staaten
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...AbgeschlossenPostakute Folgen von COVID-19 | Zustand nach COVID-19 | Lang-COVID | Chronisches COVID-19-SyndromItalien
-
Yang I. PachankisAktiv, nicht rekrutierendCOVID-19 Atemwegsinfektion | COVID-19 Stresssyndrom | COVID-19-Impfstoff-Nebenwirkung | COVID-19-assoziierte Thromboembolie | COVID-19 Post-Intensive-Care-Syndrom | COVID-19-assoziierter SchlaganfallChina